The Future of Medicare’s Coverage with Evidence Development Policy

Medicare is considering changes to an important program meant to provide beneficiaries with access to newly approved drugs and devices while collecting data on how they work in the real world. The nearly 20-year-old program, known as Coverage with Evidence Development (CED), has recently faced questions about whether it’s working as intended. 

The USC Schaeffer Center, in partnership with the Tufts Center for Evaluation of Value and Risk in Health and the Stanford Mussallem Center for Biodesign, hosted a conversation on the future of CED at USC’s Capital Campus in Washington, D.C. Attendees heard from the Centers for Medicare and Medicaid Services (CMS) official overseeing updated guidance, learned about the latest research and shared ideas on how CED could be improved.

Watch the full event:

Welcome Remarks

---

Fireside Chat

---

Review of Latest Perspectives

Darius Lakdawalla, PhD
USC Schaeffer

Joshua Makower, MD
Director
Stanford Mussallem Center for Biodesign

Peter Neumann, Sc.D
Director
Center for the Evaluation of Value and Risk in Health, Tufts Medical Center

---

Reactions: The Good, Bad and Ugly

Barry Liden, JD
USC Schaeffer

Gregory Daniel, PhD
Vice President, Global Public Policy
Eli Lilly and Company

John Dwyer, JD
Co-Founder and President
Global Alzheimer’s Platform Foundation

Perry Bridger, MHS
Senior Advisor, Public Affairs
Edwards Lifesciences

Robert McDonough 
Senior Director for Clinical Policy Research and Development
Aetna

---

Closing Remarks

Darius Lakdawalla, PhD
USC Schaeffer